Among the highlights of the American Heart Association’s annual scientific meeting (5-7 November, Chicago, Illinois, USA) were full results from the PROMINENT trial of triglyceride (TG) lowering with pemafibrate to reduce cardiovascular (CV) risk, latest updates on links between remnant cholesterol and atherosclerotic cardiovascular disease (ASCVD), and Mendelian randomisation studies of ANGPTL3 and TG levels in relation to cardiometabolic and liver diseases and acute pancreatitis.
Read the reports:
- Pemafibrate fails to reduce CV events in PROMINENT trial
- New data support remnant cholesterol measurement in risk stratification for ASCVD prevention
- Genetically-predicted blood ANGPTL3 linked to acute pancreatitis but not cardiometabolic diseases
- Mendelian randomisation study links TG levels to NAFLD independent of other lipoproteins
Reportage by Jenny Bryan